Compare SAP & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAP | JNJ |
|---|---|---|
| Founded | 1972 | 1886 |
| Country | Germany | United States |
| Employees | 100000 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.2B | 542.4B |
| IPO Year | N/A | 2003 |
| Metric | SAP | JNJ |
|---|---|---|
| Price | $155.27 | $254.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | ★ $288.00 | $238.20 |
| AVG Volume (30 Days) | 2.9M | ★ 7.7M |
| Earning Date | 04-23-2026 | 04-14-2026 |
| Dividend Yield | 1.12% | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $10.28 | $6.63 |
| Revenue Next Year | $11.76 | $7.43 |
| P/E Ratio | ★ $28.01 | $114.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $148.16 | $151.52 |
| 52 Week High | $313.28 | $251.71 |
| Indicator | SAP | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 39.64 | 72.20 |
| Support Level | N/A | $233.83 |
| Resistance Level | $178.96 | N/A |
| Average True Range (ATR) | 3.96 | 5.13 |
| MACD | -2.06 | 1.78 |
| Stochastic Oscillator | 18.98 | 99.24 |
Founded in Germany in 1972 by former IBM employees, SAP is the world's largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP's portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.